StockNews.com assumed coverage on shares of Myriad Genetics (NASDAQ:MYGN – Get Rating) in a report issued on Thursday. The brokerage issued a hold rating on the stock. MYGN has been the subject of a number of other reports. Stephens raised their price target on Myriad Genetics from $17.00 to $24.00 and gave the company an […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) issued its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02), Briefing.com reports. Myriad Genetics had a negative return on equity of 5.83% and a negative net margin of 16.51%. The business had revenue of $181.20 million […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -$0.36–$0.24 for the period, compared to the consensus earnings per share estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate […]